Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
yahoo.com
science
2022-10-17 12:00:00

Daré Bioscience, Inc.

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause



DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced positive topline efficacy results from its Phase 1 / 2 clinical trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen.
